Advances in Hepatitis E Virus (HEV)
A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Viral Pathogens".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 2254
Special Issue Editor
Special Issue Information
Dear Colleagues,
The diverse forms acquired by Hepatitis E Virus (HEV) to infect humans make it a pathogen of global relevance. HEV commonly causes self-limiting hepatitis but occasionally leads to fulminant liver failure and, in immunosuppression, chronic HEV infection. The virus is mainly transmitted via the fecal-oral route; the zoonotic potential of HEV is broadly recognized, and, it is also considered a foodborne pathogen.
HEV can be present either as a naked particle or as a quasi-enveloped virion. Both forms of the virus are infectious and allow HEV dissemination. Importantly, the quasi-envelope may facilitate the distribution of the virus to different tissues resulting in multiple extrahepatic manifestations. In humans, the progression of HEV infection in the liver is restricted by the host immune response and the pathophysiological mechanisms behind the development of extrahepatic manifestations remain to be elucidated.
There is no approved drug for the treatment of HEV, and, a vaccine licensed in China in 2011 is not widely available. Considering the WHO recommendation for eliminating infectious hepatitis by 2030, joint efforts are required to improve the diagnosis and therapy of acute and chronic hepatitis E, having virus eradication as the goal. The characterization of immune signatures associated with disease progression, extrahepatic manifestations, optimized experimental models, and the epidemiology of HEV are necessary.
This Special Issue of Pathogens collects research articles, comprehensive reviews, and short communications in line with the most recent advances in the study of HEV. I am looking forward to your valuable involvement in this interesting Issue.
Dr. Nora A. Fierro
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatitis E virus
- clinical outcome
- diagnostic
- epidemiology
- therapy
